Lymphatic Diseases
Welcome,         Profile    Billing    Logout  
 289 Companies   444 Products   444 Products   177 Mechanisms of Action   23 Trials   5319 News 


12345678910111213...109110»
  • ||||||||||  Yervoy (ipilimumab) / Ono Pharma, BMS
    Phase classification, Combination therapy:  Ipilimumab and Local Radiation for Selected Solid Tumors (clinicaltrials.gov) -  Jan 24, 2024   
    P1,  N=3, Terminated, 
    N=36 --> 18 Phase classification: P1/2 --> P1
  • ||||||||||  Trial completion, Trial completion date:  A Study for Older Adults With Acute Lymphoblastic Leukaemia (clinicaltrials.gov) -  Aug 16, 2023   
    P2,  N=126, Completed, 
    Phase classification: P=N/A --> P1 Unknown status --> Completed | Trial completion date: Jun 2022 --> Feb 2023
  • ||||||||||  Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date:  H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis (clinicaltrials.gov) -  Aug 3, 2023   
    P3,  N=0, Withdrawn, 
    Unknown status --> Completed | Trial completion date: Jun 2022 --> Feb 2023 N=476 --> 0 | Trial completion date: Feb 2010 --> Aug 2023 | Completed --> Withdrawn | Trial primary completion date: Feb 2010 --> Aug 2023
  • ||||||||||  Grafalon (rabbit anti-T-lymphocyte globulin) / Mundipharma, NeoPharm
    Trial completion:  Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD) (clinicaltrials.gov) -  Apr 20, 2019   
    P3,  N=260, Completed, 
    Completed --> Terminated; The study was closed by the Sponsor according to the protocol-specified minimum post-treatment follow-up period of 3 years. Active, not recruiting --> Completed
  • ||||||||||  Trial completion, Trial completion date, Trial primary completion date:  Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia (clinicaltrials.gov) -  Apr 20, 2019   
    P=N/A,  N=29, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> May 2018 | Trial primary completion date: Dec 2018 --> May 2018
  • ||||||||||  Adcetris (brentuximab vedotin) / Takeda, Pfizer
    Trial completion:  Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation (clinicaltrials.gov) -  Apr 20, 2019   
    P1,  N=17, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> May 2018 | Trial primary completion date: Dec 2018 --> May 2018 Active, not recruiting --> Completed
  • ||||||||||  dobutamine / Generic mfg.
    Trial completion, Phase classification, Enrollment change, Trial completion date, Trial primary completion date, MRI:  ECHOBIKE: Real Time Myocardial Contrast Echocardiography and Dobutamine Stress Perfusion Magnetic Resonance Imaging (clinicaltrials.gov) -  Mar 14, 2019   
    P=N/A,  N=124, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Jun 2018 Enrolling by invitation --> Completed | Phase classification: P1 --> PN/A | N=80 --> 124 | Trial completion date: Jun 2011 --> Mar 2019 | Trial primary completion date: Jun 2010 --> Feb 2019
  • ||||||||||  samalizumab (ALXN 6000) / The Leukemia & Lymphoma Society, AstraZeneca
    Trial termination:  Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM (clinicaltrials.gov) -  Mar 5, 2019   
    P1/2,  N=26, Terminated, 
    N=1905 --> 0 | Recruiting --> Withdrawn Completed --> Terminated; The study was terminated by the Sponsor for administrative reasons and not due to any safety concerns.
  • ||||||||||  Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Arzerra (ofatumumab) / Novartis, Genmab
    Trial completion, Trial completion date:  Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) -  Mar 5, 2019   
    P1/2,  N=46, Completed, 
    Completed --> Terminated; The study was terminated by the Sponsor for administrative reasons and not due to any safety concerns. Active, not recruiting --> Completed | Trial completion date: Jan 2020 --> Jan 2018
  • ||||||||||  Gamunex (intravenous normal human immunoglobulin 10%) / Bayer, Grifols, Kedrion
    Trial completion:  Intravenous Immunoglobulin (IVIG) in Lung Transplantation (clinicaltrials.gov) -  Mar 5, 2019   
    P2,  N=11, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed
  • ||||||||||  Campath (alemtuzumab) / Sanofi
    Trial completion, Enrollment change, Trial primary completion date, Combination therapy, IO biomarker:  ACT-1: Alemtuzumab and CHOP in T-cell Lymphoma (clinicaltrials.gov) -  Mar 1, 2019   
    P3,  N=136, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | N=308 --> 136 | Trial primary completion date: Apr 2015 --> Dec 2016
  • ||||||||||  Enrollment change, Trial termination, Post-transplantation:  Vaccine Therapy For Patients Being Considered For Organ Transplant Who Are at Risk For PTLD (clinicaltrials.gov) -  Feb 26, 2019   
    P1,  N=23, Terminated, 
    Active, not recruiting --> Completed | N=308 --> 136 | Trial primary completion date: Apr 2015 --> Dec 2016 N=40 --> 23 | Active, not recruiting --> Terminated; Loss of funding
  • ||||||||||  Enrollment closed, Phase classification:  A Study for Older Adults With Acute Lymphoblastic Leukaemia (clinicaltrials.gov) -  Feb 15, 2019   
    P2,  N=126, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: Oct 2018 --> Dec 2018 Recruiting --> Active, not recruiting | Phase classification: P3 --> P2
  • ||||||||||  milciclib (TZLS-201) / Tiziana Life Sci
    Trial termination:  Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma (clinicaltrials.gov) -  Feb 6, 2019   
    P2,  N=72, Terminated, 
    Active, not recruiting --> Terminated; For the last patient still on treated nominal therapeutic use of the Milciclib was approved at INT Milano. Active, not recruiting --> Terminated; For the 2 last patients still on treated nominal therapeutic use of the Milciclib was approved at INT Milano.
  • ||||||||||  Imbruvica (ibrutinib) / AbbVie, J&J
    Trial completion, Enrollment change, Trial completion date, Combination therapy:  Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov) -  Feb 5, 2019   
    P1/2,  N=35, Completed, 
    Active, not recruiting --> Terminated; For the 2 last patients still on treated nominal therapeutic use of the Milciclib was approved at INT Milano. Active, not recruiting --> Completed | N=56 --> 35 | Trial completion date: Nov 2017 --> Aug 2017
  • ||||||||||  dasatinib / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date:  Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) -  Feb 1, 2019   
    P1/2,  N=38, Completed, 
    Active, not recruiting --> Completed | N=56 --> 35 | Trial completion date: Nov 2017 --> Aug 2017 Active, not recruiting --> Completed | Trial completion date: May 2018 --> Dec 2017 | Trial primary completion date: Apr 2018 --> Aug 2016
  • ||||||||||  alisertib (MLN8237) / Puma, Istodax (romidepsin) / Astellas, BMS
    Trial completion, Enrollment change:  Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas (clinicaltrials.gov) -  Jan 28, 2019   
    P1,  N=26, Completed, 
    Active, not recruiting --> Completed | Trial completion date: May 2018 --> Dec 2017 | Trial primary completion date: Apr 2018 --> Aug 2016 Active, not recruiting-> Completed | N=42 --> 26
  • ||||||||||  Biomarker, Trial completion, Trial completion date:  CLEAR: CLL Empirical Antibiotic Regimen (clinicaltrials.gov) -  Jan 25, 2019   
    P2,  N=71, Completed, 
    Active, not recruiting-> Completed | N=42 --> 26 Active, not recruiting --> Completed | Trial completion date: Dec 2015 --> Mar 2016
  • ||||||||||  Trial completion, Phase classification:  Red Cell Transfusion Goals in Patients With Acute Leukemias (clinicaltrials.gov) -  Jan 24, 2019   
    P1,  N=90, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2015 --> Mar 2016 Active, not recruiting --> Completed | Phase classification: PN/A --> P1
  • ||||||||||  Cytorex EBV (baltaleucel-T) / Baylor College of Medicine, Houston Methodist Hospital, Texas Children's Hospital, Athenex
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma (clinicaltrials.gov) -  Jan 14, 2019   
    P2,  N=15, Terminated, 
    Active, not recruiting --> Completed Recruiting --> Terminated | Trial primary completion date: Sep 2018 --> Apr 2018 | N=35 --> 15 | Trial completion date: Sep 2019 --> Sep 2018; Insufficient enrollment rate
  • ||||||||||  Trial completion:  Airway Vascular Lesions (clinicaltrials.gov) -  Jan 12, 2019   
    P=N/A,  N=75, Completed, 
    Recruiting --> Terminated | Trial primary completion date: Sep 2018 --> Apr 2018 | N=35 --> 15 | Trial completion date: Sep 2019 --> Sep 2018; Insufficient enrollment rate Active, not recruiting --> Completed
  • ||||||||||  Hu-Mik-Beta-1 / National Institute of Neurological Disorders and Stroke
    Trial completion date:  Hu-Mik-beta1 to Treat T-Cell Large Granular Lymphocytic Leukemia (clinicaltrials.gov) -  Jan 11, 2019   
    P1,  N=9, Completed, 
    Active, not recruiting --> Completed Trial completion date: Nov 2010 --> Jan 2019
  • ||||||||||  Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
    Trial primary completion date:  Sequential Regimen of Bendamustin [B] Followed by GA101 and Ibrutinib [I] in CLL Patients (clinicaltrials.gov) -  Jan 11, 2019   
    P2,  N=66, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Aug 2019 --> Jan 2019 | Trial primary completion date: Aug 2019 --> Jan 2019 Trial primary completion date: Sep 2019 --> Aug 2016
  • ||||||||||  everolimus / Generic mfg., bendamustine / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date:  Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer (clinicaltrials.gov) -  Jan 4, 2019   
    P1,  N=20, Completed, 
    N=50 --> 21 | Trial completion date: Jan 2022 --> Jul 2018 | Recruiting --> Terminated; Insufficient recruitment and unavailability of the treatment Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Apr 2018 | Trial primary completion date: Dec 2018 --> Apr 2018